ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW Medical Partners With Japan's Okinawa Research Center to Combat Age-Related Diseases
ANEW MEDICAL, INC. (NASDAQ:WENA), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces a strategic partnership with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of Japan's Okinawa Research Center for Longevity Science (ORCLS) for the research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases.
ANEW醫療公司（NASDAQ：WENA）是一家生物製藥公司，專注於開發用於神經和年齡相關疾病的治療的新型疾病修正治療及特殊診斷技術的研究。宣佈與日本沖繩長壽科學研究中心的鈴木誠、Craig and Bradley Willcox、Richard Allsopp和島袋道雄博士的戰略合作，以研究和開發ANEW的Klotho基因療法，以提高壽命並減少年齡相關疾病。
'Blue Zones', as coined by National Geographic explorer and journalist Dan Buettner, are located in Ikaria, Greece; the Ogliastra Region of Sardinia; the Nicoya Peninsula in Costa Rica; and Loma Linda, California.
'藍地區，由國家地理探險家和記者丹·布特納（Dan Buettner）所起的名字，位於希臘伊卡利亞，薩爾代尼亞的Ogliastra地區，哥斯達黎加的尼科亞半島和加州洛馬林達。沖繩，最初的“藍地區”，已經成爲ORCLS近五十年來重大研究的焦點，導致發現了其他“長壽熱點” - 遍佈全球。這些區域以高濃度的壽命異常長的人群爲特徵，同時保持良好健康狀況。初步數據表明人的Klotho基因及其分泌的alpha-Klotho蛋白同工異構體可能有助於延長壽命並提供對神經退行性疾病的保護，例如肌萎縮性側索硬化症（ALS）、阿爾茨海默病（AD）和帕金森病（PD）。顯然，沖繩人在全球AD的患病率中居低位。
Okinawa, the original 'Blue Zone', has been the focus of nearly five decades of groundbreaking research by ORCLS, leading to the discovery of other "longevity hotspots" - across the world. These areas are characterized by high concentrations of people who live to exceptional ages, while maintaining good health. Preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform, may contribute to longevity and provide protection against neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD) and Parkinson's Disease (PD). Remarkably, Okinawans have among the lowest prevalence rates of AD globally.
原始的“藍地區”藍區已成爲ORCLS近五十年來重大研究的焦點導致發現了其他“長壽熱點”，這些區域以高濃度的壽命異常長的人群爲特徵同時保持良好健康狀況。人α-Klotho版本的Klotho基因和其分泌的alpha-Klotho蛋白同工異構體，可能有助於延長壽命並對抗神經退行性疾病，例如肌萎縮性側索硬化症（ALS）、阿爾茨海默病（AD）和帕金森病（PD）。α-KlothoKlotho顯然，沖繩人在全球AD的患病率中居低位。ANEW的任務是在高度未滿足的醫療需求領域提供轉化性蛋白質、細胞和基因治療，特別針對高度普遍的神經退行性疾病和年齡相關疾病，包括ALS、AD和PD。與ORCLS的合作是ANEW在日本沖繩進行的研究項目的一部分，該項目因其相對較高的極長壽命的人數而聞名，許多人都活到了100歲以上。
ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders including ALS, AD and PD. The collaboration with ORCLS is part of ANEW's research program on the extended life expectancy in Okinawa, Japan, which is renowned for its comparatively high number of people who live extremely long and healthy lives, many reaching 100 years and more.
ANEW正在開發一系列針對Klotho基因的細胞和基因治療新藥組合，以潛在治療令人沮喪的神經退行性疾病。該公司在主要市場擁有新穎的知識產權組合並正在推進臨床發展。
ANEW is developing a groundbreaking portfolio of cell and gene-based therapeutics targeting the Klotho gene for potential treatment of debilitating neurodegenerative diseases. The Company holds a portfolio of novel intellectual property in major markets and is advancing clinical development.
對Klotho基因的革命性組合細胞和基因治療的開發使ANEW能夠獲得肺病與保健市場領先者的地位，併爲患者提供前所未有的生命緩解。Klotho公司擁有新穎的在主要市場上的知識產權組合並正在推進臨床發展。
譯文內容由第三人軟體翻譯。